FY2024 EPS Estimates for TSE:HLS Reduced by Stifel Canada

HLS Therapeutics Inc. (TSE:HLS) – Analysts at Stifel Canada lowered their FY2024 earnings per share estimates for shares of HLS Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Stifel Canada analyst J. Keywood now forecasts that the company will post earnings per share of ($0.88) for the year, down from their previous estimate of ($0.86). The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q4 2024 earnings at ($0.15) EPS and FY2025 earnings at ($0.31) EPS.

Separately, Stifel Nicolaus decreased their price objective on HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.

HLS Therapeutics Stock Down 2.2 %

Shares of HLS Therapeutics stock opened at C$3.18 on Friday. The company has a market capitalization of C$101.09 million, a P/E ratio of -3.15 and a beta of 1.07. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. The business has a 50-day moving average of C$3.55 and a two-hundred day moving average of C$3.54. HLS Therapeutics has a 1 year low of C$3.00 and a 1 year high of C$5.48.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.